Twitty Christopher G, Huppert Laura A, Daud Adil I
OncoSec Inc., 3565 General Atomics Ct, San Diego, CA, 92121, USA.
Division of Hematology/Oncology, Department of Medicine, University of California, San Francisco, 1600 Divisadero Street, Rm A741, San Francisco, CA, 94143, USA.
Curr Oncol Rep. 2020 Feb 11;22(3):25. doi: 10.1007/s11912-020-0886-z.
Recent developments in immunotherapy have transformed the landscape of melanoma therapy. Here, we review markers for response to immunotherapy.
Current immunotherapies disable immune checkpoints on T cells and other immune cells and allow immune rejection of tumor. This process depends crucially on a preexisting response to the development of the melanoma. Here we describe the complexity of the anti-tumor immune response and the links to the development of markers that are currently used or under investigation in the clinic. We describe immune response biomarkers along with new developments that could translate into advances.
免疫疗法的最新进展改变了黑色素瘤治疗的格局。在此，我们综述免疫疗法反应的标志物。
目前的免疫疗法可使T细胞和其他免疫细胞上的免疫检查点失活，并允许对肿瘤进行免疫排斥。这一过程关键取决于对黑色素瘤发展预先存在的反应。在此，我们描述抗肿瘤免疫反应的复杂性以及与目前临床使用或正在研究的标志物发展的联系。我们描述了免疫反应生物标志物以及可能转化为进展的新进展。
Zotero 插件